Skip to main content
Apply for Grants

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

  • ${value}

Filter Results (2161${count})

  • Summer 2022 RFP: Accelerating the Translation of Parkinson's Disease Therapies, 2022
    Developing an Inhibitor of Transglutaminase 2 as a Disease-modifying Treatment for Parkinson’s Disease

    Study Rationale: Clumping of alpha-synuclein in the brain is a key pathological feature of Parkinson’s disease (PD) and is believed to lead to brain cell degeneration. Identifying factors that...

  • Spring 2022 RFA: Therapeutic Pipeline Program Pre-Clinical, 2022
    Assessing the Effects of USP30 Inhibitors on the Removal of Damaged Mitochondria in Nerve Cells

    Study Rationale: Mitochondrial dysfunction is extensively associated with genetic and sporadic forms of Parkinson’s disease (PD). Yet there are currently no clinical trials that specifically aim to...

  • Summer 2022 RFP: Expanding Biological Understanding of Parkinson's Disease, 2022
    Assessing Whether Cholesterol or Its Metabolites Increase the Risk of Developing Parkinson’s Disease

    Study Rationale: Parkinson’s disease (PD) has been associated with a dysregulation of cholesterol metabolism in brain cells and the accumulation of a protein called alpha-synuclein. Our research is...

  • Summer 2022 RFP: Accelerating the Translation of Parkinson's Disease Therapies, 2022
    Evaluating the Ability of HSG4112, An Anti-obesity Drug Candidate, to Protect Dopamine-producing Neurons Against Mitochondrial Dysfunction

    Study Rationale: Mitochondrial dysfunction in dopamine-producing neurons is one of the hallmarks of Parkinson’s disease (PD) pathology. Inside mitochondria is a protein called Paraoxonase 2 (PON2)...

  • Research Grant, 2022
    Development of a Safe and Efficient Method to Treat Parkinson’s Disease Using RNA-based Gene Therapy

    Study Rationale: Gene mutations are one of several cause of Parkinson’s disease (PD). Developing an efficient method for introducing functional versions of these mutated genes into cells that are...

  • Spring 2022 RFA: Target Advancement Program - Target Validation, 2022
    Examining the Action of Potassium Channels and the Inflammasome in a Signaling Axis That Can Serve as a Pharmacological Target Against Parkinson’s Disease

    Study Rationale: Both voltage-gated potassium channels and inflammatory signaling are known to be involved in Parkinson’s disease (PD). Each of these signaling systems contributes to the brain...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.